JP2008534074A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008534074A5 JP2008534074A5 JP2008503210A JP2008503210A JP2008534074A5 JP 2008534074 A5 JP2008534074 A5 JP 2008534074A5 JP 2008503210 A JP2008503210 A JP 2008503210A JP 2008503210 A JP2008503210 A JP 2008503210A JP 2008534074 A5 JP2008534074 A5 JP 2008534074A5
- Authority
- JP
- Japan
- Prior art keywords
- zotarolimus
- therapeutic composition
- control
- drug delivery
- implantation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001225 therapeutic effect Effects 0.000 claims 23
- 239000000203 mixture Substances 0.000 claims 22
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 claims 20
- 229950009819 zotarolimus Drugs 0.000 claims 20
- 238000012377 drug delivery Methods 0.000 claims 18
- 238000002513 implantation Methods 0.000 claims 15
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 11
- 229960002930 sirolimus Drugs 0.000 claims 11
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 11
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 150000002148 esters Chemical class 0.000 claims 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 4
- 206010020718 hyperplasia Diseases 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 2
- 229960002964 adalimumab Drugs 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 2
- 229960002842 clobetasol Drugs 0.000 claims 2
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 claims 2
- 230000001186 cumulative effect Effects 0.000 claims 2
- 229960003957 dexamethasone Drugs 0.000 claims 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960005309 estradiol Drugs 0.000 claims 2
- 229930182833 estradiol Natural products 0.000 claims 2
- 229960005167 everolimus Drugs 0.000 claims 2
- 229960002714 fluticasone Drugs 0.000 claims 2
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 2
- 229960000890 hydrocortisone Drugs 0.000 claims 2
- 229960001680 ibuprofen Drugs 0.000 claims 2
- 229960002009 naproxen Drugs 0.000 claims 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 2
- 229960005489 paracetamol Drugs 0.000 claims 2
- 229960000894 sulindac Drugs 0.000 claims 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 claims 1
- 102000009123 Fibrin Human genes 0.000 claims 1
- 108010073385 Fibrin Proteins 0.000 claims 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 1
- -1 adalimumab Chemical compound 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 229960004676 antithrombotic agent Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000002596 correlated effect Effects 0.000 claims 1
- 229950003499 fibrin Drugs 0.000 claims 1
- 239000003527 fibrinolytic agent Substances 0.000 claims 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 1
- 229960001302 ridaforolimus Drugs 0.000 claims 1
- 229960000235 temsirolimus Drugs 0.000 claims 1
- 229960000103 thrombolytic agent Drugs 0.000 claims 1
- YYSFXUWWPNHNAZ-PKJQJFMNSA-N umirolimus Chemical compound C1[C@@H](OC)[C@H](OCCOCC)CC[C@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 YYSFXUWWPNHNAZ-PKJQJFMNSA-N 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66448805P | 2005-03-23 | 2005-03-23 | |
| US60/664,488 | 2005-03-23 | ||
| US71508205P | 2005-09-08 | 2005-09-08 | |
| US60/715,082 | 2005-09-08 | ||
| US72687805P | 2005-10-14 | 2005-10-14 | |
| US72708005P | 2005-10-14 | 2005-10-14 | |
| US72719605P | 2005-10-14 | 2005-10-14 | |
| US60/726,878 | 2005-10-14 | ||
| US60/727,196 | 2005-10-14 | ||
| US60/727,080 | 2005-10-14 | ||
| US73257705P | 2005-10-17 | 2005-10-17 | |
| US60/732,577 | 2005-10-17 | ||
| PCT/US2006/010700 WO2007032777A2 (en) | 2005-03-23 | 2006-03-22 | Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008534074A JP2008534074A (ja) | 2008-08-28 |
| JP2008534074A5 true JP2008534074A5 (enExample) | 2009-04-30 |
| JP5242374B2 JP5242374B2 (ja) | 2013-07-24 |
Family
ID=37865406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008503210A Expired - Fee Related JP5242374B2 (ja) | 2005-03-23 | 2006-03-22 | 組成物ならびに長期効力を得るための医療機器を用いたラパマイシン類縁体の投与方法 |
Country Status (3)
| Country | Link |
|---|---|
| EP (2) | EP3138531A1 (enExample) |
| JP (1) | JP5242374B2 (enExample) |
| WO (1) | WO2007032777A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8394398B2 (en) | 1997-09-26 | 2013-03-12 | Abbott Laboratories | Methods of administering rapamycin analogs with anti-inflammatories using medical devices |
| US7357942B2 (en) | 1997-09-26 | 2008-04-15 | Abbott Laboratories | Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens |
| US8257726B2 (en) | 1997-09-26 | 2012-09-04 | Abbott Laboratories | Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices |
| US7378105B2 (en) | 1997-09-26 | 2008-05-27 | Abbott Laboratories | Drug delivery systems, kits, and methods for administering zotarolimus and paclitaxel to blood vessel lumens |
| US8431145B2 (en) | 2004-03-19 | 2013-04-30 | Abbott Laboratories | Multiple drug delivery from a balloon and a prosthesis |
| EP2068932B1 (en) * | 2006-08-15 | 2013-11-06 | Abbott Laboratories | Compositions and drug-delivery systems comprising rapamycin analogs and paclitaxel |
| KR20100085179A (ko) | 2007-09-04 | 2010-07-28 | 가부시키가이샤 니혼 스텐토 테크놀로지 | 약제 서방성 스텐트 |
| US8951595B2 (en) | 2009-12-11 | 2015-02-10 | Abbott Cardiovascular Systems Inc. | Coatings with tunable molecular architecture for drug-coated balloon |
| US20130303496A1 (en) * | 2012-05-08 | 2013-11-14 | Abbott Cardiovascular Systems Inc. | Method Of Treating Vascular Lesions |
| US9610385B2 (en) * | 2013-03-07 | 2017-04-04 | Abbott Cardiovascular Systems Inc. | Method of fabricating an implantable medical device comprising a rapamycin derivative |
| EP4255357A1 (en) * | 2020-12-29 | 2023-10-11 | Sino Medical Sciences Technology Inc. | Drug eluting stent |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| US3993749A (en) | 1974-04-12 | 1976-11-23 | Ayerst Mckenna And Harrison Ltd. | Rapamycin and process of preparation |
| US4885171A (en) | 1978-11-03 | 1989-12-05 | American Home Products Corporation | Use of rapamycin in treatment of certain tumors |
| US4316885A (en) | 1980-08-25 | 1982-02-23 | Ayerst, Mckenna And Harrison, Inc. | Acyl derivatives of rapamycin |
| US4401653A (en) | 1981-03-09 | 1983-08-30 | Ayerst, Mckenna & Harrison Inc. | Combination of rapamycin and picibanil for the treatment of tumors |
| US4894366A (en) | 1984-12-03 | 1990-01-16 | Fujisawa Pharmaceutical Company, Ltd. | Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same |
| US4650803A (en) | 1985-12-06 | 1987-03-17 | University Of Kansas | Prodrugs of rapamycin |
| US5527337A (en) | 1987-06-25 | 1996-06-18 | Duke University | Bioabsorbable stent and method of making the same |
| US4916193A (en) | 1987-12-17 | 1990-04-10 | Allied-Signal Inc. | Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides |
| US5092877A (en) | 1988-09-01 | 1992-03-03 | Corvita Corporation | Radially expandable endoprosthesis |
| US4994071A (en) | 1989-05-22 | 1991-02-19 | Cordis Corporation | Bifurcating stent apparatus and method |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| AU7998091A (en) | 1990-05-17 | 1991-12-10 | Harbor Medical Devices, Inc. | Medical device polymer |
| JPH04230389A (ja) | 1990-07-16 | 1992-08-19 | American Home Prod Corp | ラパマイシン誘導体 |
| US5023262A (en) | 1990-08-14 | 1991-06-11 | American Home Products Corporation | Hydrogenated rapamycin derivatives |
| PT98990A (pt) | 1990-09-19 | 1992-08-31 | American Home Prod | Processo para a preparacao de esteres de acidos carboxilicos de rapamicina |
| US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
| US5120727A (en) | 1991-05-29 | 1992-06-09 | American Home Products Corporation | Rapamycin dimers |
| US5120725A (en) | 1991-05-29 | 1992-06-09 | American Home Products Corporation | Bicyclic rapamycins |
| US6090901A (en) | 1991-07-05 | 2000-07-18 | Biocompatibles Limited | Polymeric surface coatings |
| US5705583A (en) | 1991-07-05 | 1998-01-06 | Biocompatibles Limited | Polymeric surface coatings |
| US5163852A (en) | 1992-02-11 | 1992-11-17 | W. L. Gore & Associates, Inc. | Coaxial cable side tape connector assembly and processes for assembly |
| US5177203A (en) | 1992-03-05 | 1993-01-05 | American Home Products Corporation | Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents |
| US5464650A (en) | 1993-04-26 | 1995-11-07 | Medtronic, Inc. | Intravascular stent and method |
| US5605696A (en) | 1995-03-30 | 1997-02-25 | Advanced Cardiovascular Systems, Inc. | Drug loaded polymeric material and method of manufacture |
| US5837313A (en) | 1995-04-19 | 1998-11-17 | Schneider (Usa) Inc | Drug release stent coating process |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| CA2256323C (en) | 1997-03-31 | 2007-05-22 | Kabushikikaisha Igaki Iryo Sekkei | Stent for vessel |
| US20040213789A1 (en) * | 1997-09-02 | 2004-10-28 | Oron Yacoby-Zeevi | Heparanase activity neutralizing anti-heparanase monoclonal antibody and other anti-heparanase antibodies |
| US20030129215A1 (en) | 1998-09-24 | 2003-07-10 | T-Ram, Inc. | Medical devices containing rapamycin analogs |
| US8029561B1 (en) | 2000-05-12 | 2011-10-04 | Cordis Corporation | Drug combination useful for prevention of restenosis |
| US6419692B1 (en) | 1999-02-03 | 2002-07-16 | Scimed Life Systems, Inc. | Surface protection method for stents and balloon catheters for drug delivery |
| GB0100760D0 (en) | 2001-01-11 | 2001-02-21 | Biocompatibles Ltd | Drug delivery from stents |
| EP2314293B1 (en) * | 2001-01-16 | 2017-01-04 | Vascular Therapies, LLC | Implantable device containing resorbable matrix material and rapamycin for preventing or treating vasuloproliferative diseases |
| US7708712B2 (en) * | 2001-09-04 | 2010-05-04 | Broncus Technologies, Inc. | Methods and devices for maintaining patency of surgically created channels in a body organ |
| EP1536850B1 (en) * | 2002-09-06 | 2016-08-10 | Abbott Laboratories | Medical device having hydration inhibitor |
| KR20060052722A (ko) * | 2003-08-05 | 2006-05-19 | 가부시키가이샤 가네카 | 생체유치용 스텐트 |
| JP4379044B2 (ja) * | 2003-08-22 | 2009-12-09 | 株式会社カネカ | 生体留置用ステント |
| US20050208093A1 (en) * | 2004-03-22 | 2005-09-22 | Thierry Glauser | Phosphoryl choline coating compositions |
| JP2008506507A (ja) * | 2004-07-19 | 2008-03-06 | ブロンカス テクノロジーズ， インコーポレイテッド | 体器官に外科的に作製されたチャネルを維持するための方法および器具 |
-
2006
- 2006-03-22 WO PCT/US2006/010700 patent/WO2007032777A2/en not_active Ceased
- 2006-03-22 EP EP16171630.3A patent/EP3138531A1/en not_active Withdrawn
- 2006-03-22 EP EP06739478A patent/EP1877004A4/en not_active Ceased
- 2006-03-22 JP JP2008503210A patent/JP5242374B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI435724B (zh) | 組合物、系統、套組及使用醫藥裝置施加雷帕黴素（ｒａｐａｍｙｃｉｎ）類似物及紫杉醇之方法 | |
| AU2003214079B2 (en) | N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents | |
| ES2479193T3 (es) | Revestimientos incluyendo acetato de dexametasona y fármacos olimus | |
| US20050020614A1 (en) | Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof | |
| Huang et al. | Drug-eluting biostable and erodible stents | |
| JP5541593B2 (ja) | ラパマイシン類似体及びパクリタキセルを含む組成物及び薬物送達システム | |
| WO2007111925A2 (en) | Zotarolimus-containing drug delivery systems for implantation into a body lumen of a subject | |
| JP2010506849A (ja) | 組成物、及び医療デバイスを用いてパクリタキセルとともにラパマイシン類似体を投与する方法 | |
| US12453624B2 (en) | Polymer-free drug eluting vascular stents | |
| JP2008534074A5 (enExample) | ||
| ES2744848T3 (es) | Dispositivo médico de liberación de inhibidor de mTOR | |
| JP2016503316A (ja) | 糖尿病患者における脈管疾患を処置する方法 | |
| JP5242374B2 (ja) | 組成物ならびに長期効力を得るための医療機器を用いたラパマイシン類縁体の投与方法 | |
| Windecker et al. | Sirolimus eluting stent: a new era in interventional cardiology? | |
| JP2015520147A (ja) | 血管病変を治療する改善された方法 | |
| Wong et al. | Drug-eluting stents: the end of restenosis? | |
| TWI484952B (zh) | 使用醫療裝置投予雷帕黴素類似物與太平洋紫杉醇之組合物及方法 | |
| TWI469771B (zh) | 提供用以治療新生血管內膜增生之藥物之控制釋放傳遞之系統及用於減少新生血管內膜增生之醫藥組合物 | |
| TWI455713B (zh) | 使用醫藥裝置投予雷帕霉素（ｒａｐａｍｙｃｉｎ）類似物以達長期功效之方法及組合物 | |
| Wilensky et al. | Rapamycin eluting stents | |
| HK1235264A1 (en) | Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy | |
| AU2009201507A1 (en) | Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof | |
| AU2007200756A1 (en) | Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof |